George M. Milne Jr. - 05 Oct 2026 Form 4 Insider Report for Amylyx Pharmaceuticals, Inc. (AMLX)

Reporting relationship: Director
Issuer ticker: AMLX
Reported as of: 05 Oct 2026
Net transaction value: -$830,904
SEC form: 4
Accepted by SEC: 07 Oct 2026, 16:00:06 UTC
Prior SEC filing: 08 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Joshua B. Cohen, as Attorney in Fact

Key filing fact

George M. Milne Jr. filed Form 4 for Amylyx Pharmaceuticals, Inc. (AMLX) on 07 Oct 2026.

Key facts

This page summarizes George M. Milne Jr.'s Form 4 filing for Amylyx Pharmaceuticals, Inc. (AMLX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 07 Oct 2026, 16:00.

Change

Previous filing in this sequence was filed on 08 Jun 2026.
Current net transaction value: -$830,904.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001179552 Primary reporting owner

MILNE GEORGE M JR

Relationship: Director
Address: C/O AMYLYX PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE
Signature: /s/ Joshua B. Cohen, as Attorney in Fact
Signature date: 07 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMLX transaction

Common Stock

Sale

Transaction value: $830,904
Shares: -30,000
Change %: -3.7%
Price: $27.70
Shares after: 782,881
Date: 05 Oct 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on April 28, 2026.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.36 to $28.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.